Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: Long-term results on efficacy and limb salvage in a selected group of patients

Journal of Surgical Oncology

Volumn 98, Issue 3, 2008, Pages 148-155

  Cherix, Stéphane ^a   Speiser, Mélanie ^b   Matter, Maurice ^a   Raffoul, Wassim ^a   Liénard, Danièle ^a   Theumann, Nicolas ^a   Mouhsine, Elyazid ^a   Mirimanoff, René Olivier ^a   Leyvraz, Serge ^a   Lejeune, Ferdy J ^a   Leyvraz, Pierre François ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Advanced extremity sarcomas; Local treatment; Multidisciplinary team work; Prevention of amputation

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALGODYSTROPHY; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; COMPARTMENT SYNDROME; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; ELBOW STIFFNESS; FEMALE; FEMORAL NAIL FATIGUE FRACTURE; HEMATOLOGIC DISEASE; HUMAN; ISOLATED LIMB PERFUSION; KIDNEY FAILURE; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NERVE PARALYSIS; NEUROLOGICAL COMPLICATION; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; SALVAGE THERAPY; SEPTIC SHOCK; SIDE EFFECT; SKIN ATROPHY; SKIN NECROSIS; SKIN PIGMENTATION; SKIN REDNESS; SKIN ULCER; SOFT TISSUE SARCOMA; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; LIMB SALVAGE; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50949108994     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21081     Document Type: Article

References (53)

1. American Cancer Society: Cancer: Facts and figures. Atlanta, GA: American Cancer Society; 1995.
2. Pollock RE, Karnell LH, Menck HR, et al.: The national cancer data base report on soft tissue sarcoma. Cancer 1996;78:2247-2257.
3. Spiro IJ, Gebhardt MC, Jennings LC, et al.: Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997;24:540-546.
4. Karakousis CP, Proimakis C, Rao U, et al.: Local recurrence and survival in soft tissue sarcomas. Ann Surg Oncol 1996;3:255-260.
5. Mann GB, Lewis JJ, Brennan MF: Adult soft tissue sarcoma. Aust NZ Surg 1999;69:336-343.
6. Williard WC, Hajdu SI, Casper ES, et al.: Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;216:615-616.
7. Stotter A: A comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;216:615-616.
8. Gustafson P, Rooser B, Rydholm A: Is local recurrence of minor importance for metastases in soft tissue sarcomas? Cancer 1991;67:2083-2086.
9. Tanabe KK, Pollock RE, Ellis LM, et al.: Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer. 1994;73:1652-1659.
10. Rahoty P, Konya A: Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol 1993;19:641-645.
11. Cany L, Bui NB, Stockle E, et al.: Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult. Bull Cancer 1992;79:1077-1085.
12. Suit HD, Proppe KH, Mankin HJ, et al.: Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981;47:2269-2274.
13. Eilber FR, Morton DL, Eckhart J, et al.: Limb salvage for skeletal and soft tissue sarcomas: Multidisciplinary preoperative therapy. Cancer 1984;53:2579-2584.
14. Shiu MH, Hilaris BS, Harrison LB: Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991; 1485-1492.
15. Wilson AN, Davis A, Bell RS, et al.: Local control of soft tissue sarcoma of the extremity. The experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
16. Taeger G, Ruchholtz S, Niebel W, et al.: Isolated extremity perfusion with TNF-alpha and melphalan in unresectable soft tissue sarcoma. Indications, principle and technique. Unfallchirurg 2004;107:619-623.
17. Klaase JM, Kroon BB, van Geel AN, et al.: Systemic leakage during Isolated limb perfusion for melanoma. Br J Surg 1993;80:1124-1126.
18. Creech O, Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-632.
19. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. Worl J Surg 1992;16:227-233.
20. Klaase JM, Kroon BB, Benckhuijsen C, et al.: Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-621.
21. Rossi CR, Vecchiato A, Foletto M, et al.: Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade sarcomas. Cancer 1994;73:2140-2146.
22. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
23. Eggermont AM, Schraffordt, Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-764; discussion 764-5.
24. Santinami M, Deraco M, Azzarelli A, et al.: Treatment of recurrent sarcoma of the extremity by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996;82:579-584.
25. Lev-Chelouche D, Abu-Abeid S, Kollander Y, Meller I, et al.: Multifocal soft tissue sarcoma: Limb salvage following hyperthermic isolated limb prefusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol 1999;70:185-189.
26. Gutman M, Inbar M, Lev-Shlush D, et al.: High dose tumor necrosis factor alpha and melphalan administrated via isolated limb perfusion for advanced limb soft tissues sarcoma results in >90% response rate and limb preservation. Cancer 1997;79:1129-1137.
27. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 2003;98:1483-1490.
28. Lejeune FJ, Lienard D, Matter M, et al.: Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006;6:6.
29. Rossi CR, Foletto M, Di Filippo F, et al.: soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999;86:1742-1749.
30. De Wilt JH, Manusama ER, van Tiel ST, et al.: Prerequisites for effective isolated limb perfusion using tumor necrosis factor-alpha and melphalan in rats. Br J Cancer. 1999;80:161-166.
31. Lejeune FJ, Pujol N, Lienard D, et al.: Limb salvage by neoadjuvant isolated limb perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000;26:669-678.
32. Trojani M, Contesso G, Coindre JM, et al.: Soft tissue sarcomas of adults; study of pathological prognostic variables and definition of a histological grading system. Int J Cancer 1984;33:37-42.
33. Guillou L, Coindre JM, Bonichon F, et al.: Comparative study of the National Cancer Institute and French Federation of Cancer Center Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
34. Sobin LH, Witteking C: UICC TNM Classification of Malignant Tumours, 6th edition. New York: Wiley; 2002.
35. Fletcher CDM, Unni KK, Mertens F: editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
36. Lejeune FJ, Lienard D, Eggermont AM, et al.: Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother 1995;5:73-81.
37. Christoforidis D, Chassot PG, Mosimann F, et al.: Isolated limb perfusion: Distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response. Arch Surg 2003;138:17-25.
38. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910.
39. WHO handbook for reporting results of cancer treatment, WHO Offset Publication No. 48, Geneva: WHO; 1979.
40. Sorkin P, Abu-Abid S, Lev D, et al.: Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1996;13:1079-1084.
41. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
42. Rothman K: 2002; Epidemiology: An introduction, 1st edition. Oxford University Press; 240 p.
43. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
44. Ihaka R, Gentleman R: R: A language for data analysis and graphics. J Comput Graph Statist 1996;5:299-314.
45. Lev-Chelouche D, Abu-Abeid S, Nakache R, et al.: Limb desmoid tumors: A possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 1999;126:963-967.
46. Vrouenraets BC, in't Veld GJ, Nieweg OE, et al.: Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999;25:503-508.
47. Olieman AF, Pras E, van Ginkel RJ, et al.: Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998;40:807-814.
48. Eggermont AM, Schraffordt Koops H, Klausner JM, et al.: Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcomas: Results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol 1999;11:497 (Abstr).
49. van Etten B, de Wilt JH, Eggermont AM: Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003;10:32-337.
50. Lans TE, Grunhagen DJ, de Wilt JH, et al.: Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005;12:406-411. Epub 2005 March 31.
51. Bonvalot S, Laplanche A, Lejeune F, et al.: Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better? Ann Oncol 2005;16:1061-1068. Epub 2005 June 1.
52. Vrouenraets BC, Keus RB, Nieweg OE, et al.: Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol 1997;65:88-94.
53. Pisters PW, Leung DH, Woodruff J, et al.: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-1689.